Search

Your search keyword '"Opris, Daniela"' showing total 104 results

Search Constraints

Start Over You searched for: Author "Opris, Daniela" Remove constraint Author: "Opris, Daniela"
104 results on '"Opris, Daniela"'

Search Results

1. Calcinosis in Rheumatic Disease Is Still an Unmet Need: A Retrospective Single-Center Study

2. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

3. Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial

4. Three-month tapering and discontinuation of long-term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.

5. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study

7. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis

8. Mapping and predicting mortality from systemic sclerosis

10. “To Be or Not To Be,” Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity

11. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study

12. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study

13. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database

14. Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research cohort of patients with systemic sclerosis

15. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

16. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: A longitudinal EUSTAR study

17. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

18. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial

19. Update of EULAR recommendations for the treatment of systemic sclerosis

20. Original papers: clinical or basic research anti-cyclic citrullinated peptide antibodies - activity markers in rheumatoid arthritis

21. Treatment of Anterior Instability of the Shoulder

23. Low vitamin D status in systemic sclerosis and the impact on disease phenotype

25. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study

27. A1.27 Serum rituximab level and other predictors for good eular response before re-treatment in rheumatoid arthritis

32. COMPARISON OF NON-RADIOGRAPHIC SPONDYLOARTHRITIS VERSUS ANKYLOSING SPONDYLITIS PATIENTS UNDERGOING BIOLOGICAL THERAPY - DATA FROM A ROMANIAN COHORT.

33. ASSESSING ANTI-TNF TROUGH LEVELS AND ITS APPLICABILITY IN DAILY PRACTICE IN SPONDYLOARTHRITIS PATIENTS.

34. THE IMMUNOGENICITY ERA - WHAT SHOULD WE KNOW ON ANTI-TNFS IN SPONDYLOARTHRITIS PATIENTS?

35. OPTIMIZING EXISTING TOOLS FOR REACHING AN ADEQUATE DISEASE CONTROL IN PATIENTS WITH SPONDYLOARTHRITIS.

39. Additional file 1: of Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial

40. Additional file 2: of Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial

41. Additional file 4: of Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial

42. Additional file 1: of Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial

43. Additional file 4: of Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial

44. Additional file 2: of Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial

45. Additional file 3: of Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial

46. Additional file 3: of Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial

47. PULMONARY NON-HODGKIN LYMPHOMA IN A PRIMARY SJÖGREN SYNDROME PATIENT.

48. DISEASE ACTIVITY PREDICTS WHOLE BODY AND REGIONAL LEAN TISSUE IN RHEUMATOID ARTHRITIS - A CROSS-SECTIONAL STUDY.

49. FACTORS ASSOCIATED WITH SEVERITY OF DISEASE IN PSORIATIC ARTHRITIS: A CROSS-SECTIONAL STUDY.

50. IS THERE AN EARLY ULTRASONOGRAPHIC PATTERN IN SALIVARY GLANDS IN BOTH PRIMARY AND SECONDARY SJÖGREN SYNDROME?

Catalog

Books, media, physical & digital resources